The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the rationale behind the Phase III MAJIC study (NCT05057494), which is comparing the combination of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
